Trials / Completed
CompletedNCT06326060
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
Investigation of the Safety and Efficacy of Once Weekly NNC0519-0130 in Participants With Overweight or Obesity - a Dose Finding Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 354 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NNC0519-0130 | NNC0519-0130 will be administered subcutaneously. |
| DRUG | Placebo | Placebo will be administered subcutaneously. |
| DRUG | Tirzepatide | Tirzepatide will be administered subcutaneously. |
Timeline
- Start date
- 2024-03-18
- Primary completion
- 2025-04-10
- Completion
- 2025-05-01
- First posted
- 2024-03-22
- Last updated
- 2026-04-15
Locations
70 sites across 3 countries: United States, Australia, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06326060. Inclusion in this directory is not an endorsement.